Phlow Corp. and Antheia Partner to Bolster U.S. Pharmaceutical Supply Chains with Advanced Manufacturing Technologies

Phlow Corp. and Antheia today announced an ongoing partnership to onshore production of essential medicines and establish more efficient, agile, and resilient pharmaceutical supply chains in the US.
CNBC: Family offices ramp up deal-making in June with bets on biotech

Antheia founder Christina Smolke told CNBC’s Inside Wealth family offices’ patient capital makes them a good fit for investing in scientific breakthroughs.
San Francisco Business Times: How a Peninsula company is brewing cheaper Narcan and more in the U.S.

A Menlo Park biotech startup’s substantial funding round signals growing interest in domestic production of critical medicine components.
Wall Street Journal: Antheia Grabs $56 Million to Make Drug Ingredients With Biotech

The U.S. relies heavily on pharmaceutical ingredients from other countries. Antheia wants to help reduce that dependence.
Endpoints News: Schott Pharma’s €100M+ Hungary expansion; Antheia’s $56M Series C raise

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Fortune: KKR ranks as top alternative asset manager in Fortune 500

Antheia, a Menlo Park, California-based pharmaceutical ingredient maker, raised $56 million in Series C funding.
Forbes: InnovationRx: Trump’s Proposed Budget Slashes Biomedical Research

Pharmaceutical ingredient manufacturer Antheia raised $56 million led by Global Health Investment Corp. at an undisclosed valuation. Cofounder and CEO Christina Smolke told Forbes she hopes to use the funds to expand the company’s production of thebaine, a key component of common pain medications.
FiercePharma: Biosynthesis specialist and Narcan ingredient maker Antheia reels in $56M in series C funding

Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a series C financing.
BioPharmaTrend: Antheia Raises $56M Series C to Scale Biosynthetic Drug Ingredient Production, Expands to Asia

Menlo Park–based biomanufacturing company Antheia, founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, announced a $56 million Series C funding round led by Global Health Investment Corporation (GHIC) and EDBI.
SynBioBeta: Antheia Raises $56M Series C to Alleviate Global Drug Shortages with Synthetic Biology

Antheia has raised $56 million in a Series C financing round to accelerate its synthetic biology platform, which harnesses engineered yeast to produce essential pharmaceutical ingredients in weeks instead of years, positioning the company to tackle chronic global drug shortages.